Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Polycythemia Vera 2Thrombocythemia, Essential 1Primary Myelofibrosis 1

Interventions

ruxolitinib 6Hydroxyurea 3fludarabine phosphate 2bomedemstat 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Injections 2Cyclophosphamide 2Busulfan 2Biopsy 2veliparib 1umbralisib 1piperine 1iadademstat 1givinostat hydrochloride 1givinostat 1fludarabine 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1Transplantation 1Topotecan 1Stem Cell Transplantation 1Sirolimus 1Resistance Training 1Radiotherapy 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Polycythemia Vera × bomedemstat × 90 days × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡